[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 3 of about 3
1. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP, National Academy of Clinical Biochemistry: National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem; 2008 Dec;54(12):e11-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
  • BACKGROUND: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed.
  • METHODS: Published reports relevant to use of tumor markers for 5 cancer sites--testicular, prostate, colorectal, breast, and ovarian--were critically reviewed.
  • RESULTS: For testicular cancer, alpha-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. alpha-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors.
  • Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 microg/L.
  • CA125 is recommended (with transvaginal ultrasound) for early detection of ovarian cancer in women at high risk for this disease.
  • CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer.
  • CONCLUSIONS: Implementation of these recommendations should encourage optimal use of tumor markers.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. Clinical Laboratory Techniques. Colorectal Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis. Prostatic Neoplasms / diagnosis. Testicular Neoplasms / diagnosis


2. Szpakowski M, Nowińska A, Kufelnicka M, Komorowski D, Wilczyński JR: [Laparoscopy or laparotomy in the treatment of ovarian teratomas?]. Ginekol Pol; 2006 Jul;77(7):502-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopy or laparotomy in the treatment of ovarian teratomas?].
  • BACKGROUND: Mature cystic teratomas (dermoid cyst), are the most common germ cell tumours of the ovary in women of reproductive age.
  • Frequently, ultrasonography is diagnostic.
  • MATERIALS AND METHODS: 81 patients who had surgery in 3rd Departament of Gynecology and Obstetrics, University of Medicine, Lódź, from 2000 to 2005 for benign cystic teratomas were analyzed.
  • In 46 cases there were cystectomies performed sparing fragments of healthy ovarian tissue, in 24 cases ovariectomies and in 11 panhysterectomies were made.
  • All removed lesions histologically appeared benign cystis ovarian teratomas without any signs of malignancy.
  • CONCLUSIONS: The teratomas are composed of mature tissues derived from the three germ cell layers.
  • One of the possibility of ovarian teratoma's treatment is operative laparoscopy.
  • [MeSH-major] Laparoscopy. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / surgery. Teratoma / diagnosis. Teratoma / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076199.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


Advertisement
3. Wolff EF, Hughes M, Merino MJ, Reynolds JC, Davis JL, Cochran CS, Celi FS: Expression of benign and malignant thyroid tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive follicular variant of papillary thyroid cancer. Thyroid; 2010 Sep;20(9):981-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of benign and malignant thyroid tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive follicular variant of papillary thyroid cancer.
  • BACKGROUND: The most common type of ovarian germ cell tumor is the teratoma.
  • Thyroid tissue, both benign and malignant, may be a component of an ovarian teratoma.
  • Here we review this topic and illustrate major features by presenting multimodal management of a patient with BRAF-positive disseminated follicular thyroid cancer arising in an ovarian teratoma.
  • SUMMARY: Malignant thyroid tissue is often difficult to distinguish from benign thyroid tissue arising in ovarian teratomas.
  • Preoperatively, an elevated thyroglobulin (Tg) level, laboratory or clinical evidence of hyperthyroidism, or ultrasonography appearance of "struma pearl" should prompt referral to oncologist for surgical management of a possibly malignant ovarian teratoma.
  • Postoperatively, tumor tissue should be referred to pathologists experienced with differentiating benign from malignant struma ovarii.
  • We cared for woman with disseminated thyroid cancer arising in an ovarian teratoma whose history illustrates the complexity of managing ovarian teratomas with malignant thyroid tissue.
  • At age 33 she had an intraoperative rupture of an ovarian cyst, thought to be struma ovarii.
  • The tumor was found to be BRAF mutation positive (K601E).
  • CONCLUSIONS: Aggressive multimodal management appears to be the most promising approach for malignant thyroid tissue arising in ovarian teratomas.






Advertisement